Longitudinal clinical, laboratory, cytogenetic, and therapeutic data. Trilineage hematologic recovery and full donor chimerism were achieved, with molecular response (TP53 VAF clearance), sustained remission, and complete chimerism. Two cycles of azacitidine were applied according to the service protocol, and the dose of azacitidine was 75 mg/m2 per day for 7 days. For each cycle, the whole dose is calculated in milligrams and divided along the week to receive 1 or 2 complete vials per day.12 The second cycle was postponed due to serious infectious complications (cellulitis). AZA, azacitidine; cGVHD, chronic graft-versus-host disease; MTX, methotrexate; PB, peripheral blood; STR, short tandem.
Figure 2.

Longitudinal clinical, laboratory, cytogenetic, and therapeutic data. Trilineage hematologic recovery and full donor chimerism were achieved, with molecular response (TP53 VAF clearance), sustained remission, and complete chimerism. Two cycles of azacitidine were applied according to the service protocol, and the dose of azacitidine was 75 mg/m2 per day for 7 days. For each cycle, the whole dose is calculated in milligrams and divided along the week to receive 1 or 2 complete vials per day.12 The second cycle was postponed due to serious infectious complications (cellulitis). AZA, azacitidine; cGVHD, chronic graft-versus-host disease; MTX, methotrexate; PB, peripheral blood; STR, short tandem.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal